Medicare Part D Cost Trends: A Good News/Bad News Story For Biopharma
Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.
You may also be interested in...
HHS Office of Inspector General joins legislators and policy experts in warning about sharp increases in Medicare spending on catastrophic coverage in Part D.
Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.
Advisory group’s cost control recommendations on reinsurance, partial fills, and preferred specialty tiers could end up on the legislative agenda, particularly if Hillary Clinton is president.